Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Y Juarranz

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Annals of the New York Academy of Sciences|August 5, 2006
VIP-PACAP system in immunity: new insights for multitarget therapyR P Gomariz, Y Juarranz, C Abad, et al.
Neuroimmunomodulation|August 1, 2008
Vasoactive intestinal peptide as a healing mediator in Crohn's diseaseA Arranz, C Abad, Y Juarranz, et al.
Current Pharmaceutical Design|December 25, 2009
Peptides targeting Toll-like receptor signalling pathways for novel immune therapeuticsR P Gomariz, I Gutiérrez-Cañas, A Arranz, et al.
Peptides|August 21, 2007
Regulation of TLR expression, a new perspective for the role of VIP in immunityR P Gomariz, A Arranz, Y Juarranz, et al.
Annals of the New York Academy of Sciences|August 5, 2006
VIP decreases TLR4 expression induced by LPS and TNF-alpha treatment in human synovial fibroblastsY Juarranz, I Gutiérrez-Cañas, A Arranz, et al.
Annals of the New York Academy of Sciences|August 5, 2006
VIP and tolerance induction in autoimmunityF Rosignoli, M Torroba, Y Juarranz, et al.
Rheumatology (Oxford, England)|December 2, 2005
VIP down-regulates TLR4 expression and TLR4-mediated chemokine production in human rheumatoid synovial fibroblastsI Gutiérrez-Cañas, Y Juarranz, B Santiago, et al.
Scientific Reports|May 16, 2019
Activation of Th lymphocytes alters pattern expression and cellular location of VIP receptors in healthy donors and early arthritis patientsR Villanueva-Romero, I Gutiérrez-Cañas, M Carrión, et al.
Scientific Reports|August 5, 2020
Vasoactive intestinal peptide axis is dysfunctional in patients with Graves' diseaseM Carrión, A M Ramos-Leví, I V Seoane, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Annals of the New York Academy of Sciences|August 5, 2006
VIP-PACAP system in immunity: new insights for multitarget therapyR P Gomariz, Y Juarranz, C Abad, et al.
Neuroimmunomodulation|August 1, 2008
Vasoactive intestinal peptide as a healing mediator in Crohn's diseaseA Arranz, C Abad, Y Juarranz, et al.
Current Pharmaceutical Design|December 25, 2009
Peptides targeting Toll-like receptor signalling pathways for novel immune therapeuticsR P Gomariz, I Gutiérrez-Cañas, A Arranz, et al.
Peptides|August 21, 2007
Regulation of TLR expression, a new perspective for the role of VIP in immunityR P Gomariz, A Arranz, Y Juarranz, et al.
Annals of the New York Academy of Sciences|August 5, 2006
VIP decreases TLR4 expression induced by LPS and TNF-alpha treatment in human synovial fibroblastsY Juarranz, I Gutiérrez-Cañas, A Arranz, et al.
Annals of the New York Academy of Sciences|August 5, 2006
VIP and tolerance induction in autoimmunityF Rosignoli, M Torroba, Y Juarranz, et al.
Rheumatology (Oxford, England)|December 2, 2005
VIP down-regulates TLR4 expression and TLR4-mediated chemokine production in human rheumatoid synovial fibroblastsI Gutiérrez-Cañas, Y Juarranz, B Santiago, et al.
Scientific Reports|May 16, 2019
Activation of Th lymphocytes alters pattern expression and cellular location of VIP receptors in healthy donors and early arthritis patientsR Villanueva-Romero, I Gutiérrez-Cañas, M Carrión, et al.
Scientific Reports|August 5, 2020
Vasoactive intestinal peptide axis is dysfunctional in patients with Graves' diseaseM Carrión, A M Ramos-Leví, I V Seoane, et al.
Pageof 1